Next Article in Journal
Myalgic Encephalomyelitis (ME) or What? An Operational Definition
Previous Article in Journal
Genome-Based Classification and Therapy of Prostate Cancer
Previous Article in Special Issue
The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Diagnostics 2018, 8(3), 63; https://doi.org/10.3390/diagnostics8030063

Circulating Tumor Cells for the Management of Renal Cell Carcinoma

1
INSERM Unit 1151, Faculté de Médecine, Université Paris Descartes, 75014 Paris, France
2
Laboratoire de Biochimie A, Hôpital Necker-Enfants Malades, 75015 Paris, France
*
Author to whom correspondence should be addressed.
Received: 7 August 2018 / Revised: 30 August 2018 / Accepted: 31 August 2018 / Published: 3 September 2018
(This article belongs to the Special Issue Circulating Tumor Cells as Cancer Diagnostic Biomarkers)
Full-Text   |   PDF [1249 KB, uploaded 3 September 2018]   |  

Abstract

Renal cell carcinoma is a highly malignant cancer that would benefit from non-invasive innovative markers providing early diagnosis and recurrence detection. Circulating tumor cells are a particularly promising marker of tumor invasion that could be used to improve the management of patients with RCC. However, the extensive genetic and immunophenotypic heterogeneity of cells from RCC and their trend to transition to the mesenchymal phenotype when they circulate in blood constitute a challenge for their sensitive and specific detection. This review analyzes published studies targeting CTC in patients with RCC, in the context of the biological, pathological, and molecular complexity of this particular cancer. Although further analytical and clinical studies are needed to pinpoint the most suitable approach for highly sensitive CTC detection in RCC patients, it is clear that this field can bring a relevant guide to clinicians and help to RCC patients. Furthermore, as described, a particular subtype of RCC—the ccRCC—can be used as a model to study the relationship between cytomorphological and genetic cellular markers of malignancy, an important issue for the study of CTC from any type of solid cancer. View Full-Text
Keywords: circulating tumor cells (CTC); clear cell renal cell carcinoma (ccRCC); liquid biopsy; circulating cancer cells (CCC); Isolation by Size of Tumor cells (ISET) circulating tumor cells (CTC); clear cell renal cell carcinoma (ccRCC); liquid biopsy; circulating cancer cells (CCC); Isolation by Size of Tumor cells (ISET)
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Broncy, L.; Paterlini-Bréchot, P. Circulating Tumor Cells for the Management of Renal Cell Carcinoma. Diagnostics 2018, 8, 63.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top